News & Resources

Mandatory Counseling With Remote Cancer Genetic Testing May Cause More Harm Than Good

Despite recommendations from the US Preventive Services Task Force, less than 10% of women with a suggestive family history of hereditary breast and ovarian cancer receive genetic testing. Multiple barriers include low population awareness, multiple steps to accessing genetic testing and services, mandatory in-person visits for pretest and posttest counseling, and socioeconomic factors, as well as a shortage of genetic counselors. It has been suggested that mandating genetic counseling can even cause psychologic harm. Dr Elizabeth Swisher and colleagues conducted a large, randomized study (Making Genetic Testing Accessible [MAGENTA]) to assess whether omitting mandatory pretest and/or posttest genetic counseling would increase distress during remote cancer genetic screening among a large population of women (N = 3,839).

Participants in the trial were randomized to 4 arms: 1 with no mandated counseling, 1 with mandated posttest counseling, 1 with mandated pretest counseling, and a control arm with both pretest and posttest telephone counseling. At 3 and 12 months, distress (measured by the Impact of Event Scale) among women with a family history or familial pathogenic variants was not significantly different across the study arms as compared with the control arm. Overall, the elimination of pretest and/or posttest counseling was not shown to increase anxiety or depression or negatively impact completion rates. Additionally, counselors reported that participants rarely (<5%) reached out for additional counseling.

The results of this study support the option of a less intensive counseling approach in the provision of cancer genetic risk assessment. The authors suggest implementing an alternative approach to genetic testing delivery, with pretest information provided electronically and posttest counseling for those with pathogenic variants or for those without pathogenic variants who request counseling. Ultimately, honoring the preferences of low-risk individuals to skip counseling is unlikely to increase distress.

High level
The outcomes of this study suggest that mandatory individualized pretest and posttest counseling may introduce barriers to remote cancer genetic screening for some patients. Elimination of mandatory counseling did not affect completion rates and may provide more flexibility for some while reducing costs. Interestingly, the highest test completion rates occurred in the arms that did not have mandated pretest counseling. To address health disparities, studies specifically targeting certain groups are needed to determine how best to equitably provide cancer genetic risk assessment. The authors also recommend use of alternative community strategies to increase diversity and engagement among a broader population.

Ground level
Even in the setting of remote care delivery and telephone counseling, the requirement for pretest genetic counseling may serve as a barrier to test completion for some patients. Dr Swisher suggested implementation of a patient-centric remote cancer genetic testing model, in which patients are given the option to decide for themselves whether to receive pretest and/or posttest genetic counseling, as well as the option for remote, home-based testing. This may potentially remove some of the barriers and lead more people to complete genetic testing when recommended. Family and community healthcare providers have an important role in encouraging people with a family history of cancer to undergo genetic testing to help guide cancer prevention strategies and care plans, if appropriate.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.